logo-loader

e-Therapeutics 'purposefully going out to the world' to engage with big pharma

Published: 03:22 09 Aug 2017 EDT

Ray Barlow, chief executive of e-Therapeutics plc (LON:ETX) caught up with Proactive to update on developments at the drug developer.

Last month they unveiled the results of its strategic review under the new chief executive.

Following the review, the company decided to invest in its network-driven drug discovery (NDD) platform in creating new drugs, while continuing to control costs.

''The first three months of my tenure have been internally-facing .. we're now very purposefully going out to the world'', Barlow says.

''We're going to undertake a very  systematic business development exercise, we're going to engage with biopharmaceutical companies ... we're also going to engage with companies that may not be traditionally associated with this space - such as the googles of this world''.

e-Therapeutics present at the Proactive One2One Investor Forum - October 26th

Ali Mortazavi, CEO of e-Therapeutics PLC (AIM:ETX, OTCQX:ETXPF), addressed the challenges of traditional drug discovery, emphasising its high risk, extensive timeline, and considerable cost at the Proactive One2One Investor Forum. Underlining the inefficiencies of this model, Mortazavi posed...

on 11/01/2023